Drug Repositioning Service Market Growth Outlook Reveals A CAGR Of 6.1% And A Market Value Of $45.92 Billion By 2030
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Drug Repositioning Service Market Expansion Outlook: What Revenue Opportunities Lie Ahead?
The drug repositioning service market has experienced robust expansion in recent years. Valued at $34.2 billion in 2025, it is projected to reach $36.19 billion by 2026, reflecting a compound annual growth rate (CAGR) of 5.8%. This historical growth has been driven by several key factors, including the rising costs of pharmaceutical research and development, the availability of vast amounts of existing drug data, an increasing number of unsuccessful clinical trials, a heightened need for accelerated drug development timelines, and the early integration of computational approaches to drug discovery.
The drug repositioning service market is projected to experience significant expansion over the coming years. By 2030, it is anticipated to reach $45.92 billion, achieving a compound annual growth rate (CAGR) of 6.1%. This upward trajectory in the forecast period is driven by the growing need for cost-effective drug development methods, the rising implementation of artificial intelligence in discovery tools, an intensified emphasis on rare and orphan diseases, the broadening scope of data-driven clinical studies, and greater regulatory support for repurposed medications. Among the key developments shaping this period are the growing deployment of AI-centered drug repurposing systems, heightened attention to reassessing failed clinical compounds, the expanding incorporation of real-world evidence into discovery efforts, the advancement of precision medicine-focused repositioning strategies, and stronger partnerships between pharmaceutical companies and contract research organizations.
Download A Free Sample Report For Comprehensive Market Insights:
#Drug Repositioning Service Market Growth Factors: Which Forces Are Supporting Market Expansion?
The projected increase in healthcare spending is expected to drive the expansion of the drug repositioning service market. Healthcare expenditures encompass the total amount of money allocated to health services, covering prevention, treatment, rehabilitation, and administration. The growth in these expenditures is largely attributed to climbing medical costs fueled by technological advancements and a heightened demand for healthcare services. Higher levels of healthcare spending benefit drug repositioning services by enabling more extensive funding for clinical trials and research, thereby speeding up the process of discovering new therapeutic applications for existing drugs. For example, in May 2024, the Office for National Statistics, a UK government department, reported that total healthcare expenditure rose notably by 5.6% in nominal terms between 2022 and 2023. Consequently, the rise in healthcare expenditures is fueling the growth of the drug repositioning service market.
Drug Repositioning Service Market Categorization By Product Type And Application
The drug repositioning service market covered in this report is segmented –
1) By Type: Generic Drugs, Clinical Trial Failed Drugs
2) By Therapeutic Area: Oncology, Neurology, Infectious Diseases, Cardiovascular Diseases, Other Therapeutic Area
3) By End-User: Pharmaceutical Companies, Biotechnology Firms, Contract Research Organizations (CROs), Academic Research Institutions, Hospitals And Ambulatory Surgical Centers.
Subsegments:
1) By Generic Drugs: Small Molecule Drugs, Biologics, Biosimilars, Peptide-Based Drugs
2) By Clinical Trial Failed Drugs: Phase I Failed Drugs, Phase II Failed Drugs, Phase III Failed Drugs, Safety-Related Failed Drugs, Efficacy-Related Failed Drugs
Drug Repositioning Service Market Industry Trends: What Changes Are Reshaping Demand?
Major industry players in the drug repositioning service market are increasingly turning to artificial intelligence (AI) integration within drug repositioning, specifically through computational drug repositioning systems that methodically pinpoint new therapeutic applications for established medications. This process leverages AI-driven evaluation of scientific literature and biological datasets. A computational drug repositioning system is defined as a technologically advanced platform that employs artificial intelligence, machine learning, and data mining techniques to systematically scrutinize existing drugs, chemical compounds, and biological information. In November 2024, for example, Japanese corporations UBE and FRONTEO initiated a co-creation project designed to provide a collaborative structure that amalgamates their respective areas of expertise to bolster drug repositioning initiatives. This project facilitates effective interaction between dry research (centered on data analysis) and wet research (focused on biological experimentation), thereby enhancing the transition from generating hypotheses to conducting experimental verification. By capitalizing on FRONTEO’s AI-powered Drug Discovery AI Factory and KIBIT technology, this initiative systematically discovers previously unidentified links between diseases and molecular entities.
Drug Repositioning Service Market Company Landscape And Strategic Competition
Major companies operating in the drug repositioning service market are Recursion Pharmaceuticals Inc., Excelra, LifeArc, Cosmos Health Inc., Fios Genomics, Insilico Medicine Inc., Melior Discovery, Delta4, Acubiosys, VeriSIM Life, BioXcel Therapeutics Inc., Pharnext S.S., NuMedii, GVK Biosciences, Plex Research, Paradigm Biopharmaceuticals, BenevolentAI Limited
Access The Complete Drug Repositioning Service Market Report:
Drug Repositioning Service Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the drug repositioning service market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug repositioning service market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
